Adma Biologics Shares Drop 4.24% as EPS Estimate Rises 3.66%
Adma Biologics shares fell 4.24%, underperforming the S&P 500’s 1.57% decline and posting a 10.94% month-to-date drop versus the Medical sector’s 0.8% loss. Analysts forecast 2026 EPS of $0.57 (+16.3% YoY) on flat revenue and a forward P/E of 19.15 below the 19.61 industry average after a 3.66% estimate rise.
1. Stock performance overview
Adma Biologics shares declined 4.24% in the latest session, lagging the S&P 500’s 1.57% drop and marking a 10.94% month-to-date decrease compared to the Medical sector’s 0.8% loss.
2. Analyst forecasts and rating
Analysts project fiscal 2026 EPS of $0.57, up 16.3% year-over-year, on flat revenue forecasts. Consensus EPS estimates rose 3.66% over the past 30 days, resulting in a #2 Buy rating.
3. Valuation and industry position
The shares trade at a forward P/E of 19.15, modestly below the 19.61 average for its industry. The Medical - Biomedical and Genetics segment ranks 86th among 250 industries, placing it in the top 36%.